Published in Neuroreport on December 20, 1994
Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry (2008) 1.64
Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration. Mol Pharmacol (2006) 1.24
A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS One (2010) 1.13
Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology (2010) 0.97
Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse. Br J Pharmacol (2004) 0.93
Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex (2007) 1.45
The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. Br J Pharmacol (2007) 1.18
In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J Neuroimmunol (2000) 1.15
Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. Cell Mol Life Sci (2004) 1.09
Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids (2002) 1.09
Highly pathogenic H7N7 avian influenza in Italy. Vet Rec (2014) 1.08
5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem (2007) 1.05
The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci (2006) 1.04
Long lasting consequences of cannabis exposure in adolescence. Mol Cell Endocrinol (2008) 1.02
CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology (2007) 1.02
The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J Neuroimmunol (2004) 1.01
The depressive phenotype induced in adult female rats by adolescent exposure to THC is associated with cognitive impairment and altered neuroplasticity in the prefrontal cortex. Neurotox Res (2009) 1.01
Neurobiological alterations at adult age triggered by adolescent exposure to cannabinoids. Pharmacol Res (2009) 1.00
Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. Br J Pharmacol (2003) 1.00
Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940. J Neurochem (2000) 0.97
Mu opioid receptor signaling in morphine sensitization. Neuroscience (2003) 0.96
Cannabinoids, immune system and cytokine network. Curr Pharm Des (2006) 0.96
Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. Neuropharmacology (2000) 0.96
Synthesis of opiate peptides by a clonal pituitary tumor cell line. Proc Natl Acad Sci U S A (1977) 0.95
Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci (1983) 0.93
Chronic URB597 treatment at adulthood reverted most depressive-like symptoms induced by adolescent exposure to THC in female rats. Neuropharmacology (2010) 0.92
Cellular mechanisms underlying the interaction between cannabinoid and opioid system. Curr Drug Targets (2010) 0.90
Influenza A pandemic (H1N1) 2009 virus outbreak in a cat colony in Italy. Zoonoses Public Health (2011) 0.90
Effect of intracerebroventricular administration of morphine upon intestinal motility in rat and its antagonism with naloxone. Eur J Pharmacol (1977) 0.90
Presence of a reduced opioid response in interleukin-6 knock out mice. Eur J Neurosci (1999) 0.90
Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity. Eur J Pharmacol (2000) 0.89
Cannabidiol inhibits angiogenesis by multiple mechanisms. Br J Pharmacol (2012) 0.89
Gender-dependent behavioral and biochemical effects of adolescent delta-9-tetrahydrocannabinol in adult maternally deprived rats. Neuroscience (2011) 0.88
Modulation of rat brain cannabinoid receptors after chronic morphine treatment. Neuroreport (1997) 0.88
Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression. J Pharmacol Exp Ther (1998) 0.88
Cross-tolerance and convergent dependence between morphine and cannabimimetic agent WIN 55,212-2 in the guinea-pig ileum myenteric plexus. Eur J Pharmacol (1999) 0.88
Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome. Life Sci (2000) 0.87
A longitudinal study of velogenic Newcastle disease virus genotypes isolated in Italy between 1960 and 2000. Avian Pathol (2001) 0.87
Dermorphin interaction with peripheral opioid receptors. Neuropeptides (1984) 0.86
Mice heterozygous for the oxytocin receptor gene (Oxtr(+/-)) show impaired social behaviour but not increased aggression or cognitive inflexibility: evidence of a selective haploinsufficiency gene effect. J Neuroendocrinol (2013) 0.86
Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system. Eur J Pharmacol (2001) 0.86
Loss of cannabinoid-stimulated guanosine 5'-O-(3-[(35)S]Thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats. J Neurochem (2000) 0.86
Pertussis toxin inhibits the antinociceptive action of morphine in the rat. Eur J Pharmacol (1986) 0.85
Precipitated and spontaneous withdrawal in rats tolerant to anandamide. Psychopharmacology (Berl) (2000) 0.85
Involvement of CDC25Mm/Ras-GRF1-dependent signaling in the control of neuronal excitability. Mol Cell Neurosci (2001) 0.85
In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: behavioral and cellular responses after acute and chronic treatments. Synapse (2000) 0.85
The psychoactive ingredient of marijuana induces behavioural sensitization. Eur J Neurosci (2001) 0.83
Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects. J Neuroimmunol (2001) 0.83
Cellular mechanisms of Delta 9-tetrahydrocannabinol behavioural sensitization. Eur J Neurosci (2003) 0.81
Regulation of immune functions in rat splenocytes after acute and chronic in vivo treatment with CP-55,940, a synthetic cannabinoid compound. J Neuroimmunol (1997) 0.81
Effect of morphine and methadone acute treatment on immunological activity in mice: pharmacokinetic and pharmacodynamic correlates. J Pharmacol Exp Ther (1994) 0.80
Immune function alterations in mice tolerant to delta9-tetrahydrocannabinol: functional and biochemical parameters. J Neuroimmunol (1998) 0.80
A role of nitric oxide in WIN 55,212-2 tolerance in mice. Eur J Pharmacol (1998) 0.80
Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system. Brain Res Mol Brain Res (1997) 0.79
Development of a feed additive to reduce caecal Campylobacter jejuni in broilers at slaughter age: from in vitro to in vivo, a proof of concept. J Appl Microbiol (2012) 0.79
Central and peripheral components of dermorphin's effect on rat intestinal propulsion in comparison to morphine. Peptides (1983) 0.79
Chronic blockade of CB(1) receptors reverses startle gating deficits and associated neurochemical alterations in rats reared in isolation. Br J Pharmacol (2012) 0.79
Pertussis toxin inhibits morphine analgesia and prevents opiate dependence. Pharmacol Biochem Behav (1990) 0.78
International guidelines and educational experiences in an out-patient clinic for asthma. Monaldi Arch Chest Dis (1995) 0.77
Cerebral extract from morphine-tolerant rats shows antiopiate properties in guinea pig ileum bioassay. Pharmacol Res Commun (1988) 0.77
Perinatal delta9-tetrahydrocannabinol exposure did not alter dopamine transporter and tyrosine hydroxylase mRNA levels in midbrain dopaminergic neurons of adult male and female rats. Neurotoxicol Teratol (1998) 0.77
Effect on intestinal transit of neurotensin administered intracerebroventricularly to rats. Life Sci (1983) 0.76
In situ hybridization reveals specific increases in G alpha s and G alpha o mRNA in discrete brain regions of morphine-tolerant rats. Eur J Pharmacol (1993) 0.76
Increase of plasma corticosterone induced by loperamide in rats. Eur J Pharmacol (1982) 0.76
Intestinal effect of morphine 6-glucuronide: in vivo and in vitro characterization. Eur J Pharmacol (1994) 0.76
Morphine withdrawal syndrome and G protein expression: a study of the time course in the rat central nervous system. Eur J Neurosci (1995) 0.76
Effect of chronic exposure to naltrexone and opioid selective agonists on G protein mRNA levels in the rat nervous system. Brain Res Mol Brain Res (1994) 0.76
Histamine as a central modulator of rat intestinal transit. J Pharmacol Exp Ther (1989) 0.76
Cerebral sites of central action of dermorphin on intestinal motility in the rat. Peptides (1985) 0.76
Cold stress in the rat induces parallel changes in plasma and pituitary levels of endorphin and ACTH. Pharmacol Res Commun (1983) 0.76
Changes in rat spleen cannabinoid receptors after chronic CP-55,940: an autoradiographic study. Pharmacol Biochem Behav (1997) 0.76